IL134656A - Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies - Google Patents

Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies

Info

Publication number
IL134656A
IL134656A IL134656A IL13465693A IL134656A IL 134656 A IL134656 A IL 134656A IL 134656 A IL134656 A IL 134656A IL 13465693 A IL13465693 A IL 13465693A IL 134656 A IL134656 A IL 134656A
Authority
IL
Israel
Prior art keywords
noggin
embryos
leu
neural
seq
Prior art date
Application number
IL134656A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ California
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Regeneron Pharma filed Critical Univ California
Publication of IL134656A publication Critical patent/IL134656A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL134656A 1992-09-03 1993-09-02 Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies IL134656A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93995492A 1992-09-03 1992-09-03
US95041092A 1992-09-23 1992-09-23
US95740192A 1992-10-06 1992-10-06

Publications (1)

Publication Number Publication Date
IL134656A true IL134656A (en) 2006-12-10

Family

ID=27420696

Family Applications (2)

Application Number Title Priority Date Filing Date
IL106894A IL106894A0 (en) 1992-09-03 1993-09-02 Dorsal tissue affecting factor and compositions
IL134656A IL134656A (en) 1992-09-03 1993-09-02 Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL106894A IL106894A0 (en) 1992-09-03 1993-09-02 Dorsal tissue affecting factor and compositions

Country Status (9)

Country Link
US (4) US5843775A (xx)
EP (1) EP0656062B1 (xx)
JP (1) JP3431153B2 (xx)
AT (1) ATE190352T1 (xx)
AU (1) AU676847B2 (xx)
DE (1) DE69328025T2 (xx)
HK (1) HK1008347A1 (xx)
IL (2) IL106894A0 (xx)
WO (1) WO1994005791A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
AU6267098A (en) * 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
JP4357003B2 (ja) * 1997-02-19 2009-11-04 リジェネロン ファーマシューティカルズ,インコーポレイテッド 形態形成タンパク質
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999061044A1 (en) * 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
AU3667100A (en) * 1999-04-23 2000-11-10 Sulzer Orthopedics Ltd Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
CA2411914C (en) * 2000-06-20 2012-08-21 Es Cell International Pte Ltd Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists
US20020159986A1 (en) * 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
KR101163171B1 (ko) 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
WO2010147803A2 (en) * 2009-06-08 2010-12-23 Regents Of The University Of Michigan Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
JP2016530243A (ja) * 2013-07-18 2016-09-29 アン アンド ロバート エイチ.ルリー チルドレンズ ホスピタル オブ シカゴ 神経管欠損症を検出及び治療する組成物及び方法
US10179111B2 (en) * 2014-03-07 2019-01-15 University of Pittsburgh—of the Commonwealth System of Higher Education Treating soft tissue via controlled drug release
AT521641B1 (de) * 2018-09-12 2020-07-15 Fianostics Gmbh Verfahren zur Diagnose von Lebererkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (en) * 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
EP0218692A4 (en) * 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
CA2122491A1 (en) * 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions

Also Published As

Publication number Publication date
DE69328025T2 (de) 2000-11-02
ATE190352T1 (de) 2000-03-15
EP0656062B1 (en) 2000-03-08
US5843775A (en) 1998-12-01
IL106894A0 (en) 1994-05-30
JP3431153B2 (ja) 2003-07-28
US6277593B1 (en) 2001-08-21
HK1008347A1 (en) 1999-05-07
DE69328025D1 (de) 2000-04-13
US5821124A (en) 1998-10-13
WO1994005791A3 (en) 1994-07-07
US20020102643A1 (en) 2002-08-01
EP0656062A1 (en) 1995-06-07
AU676847B2 (en) 1997-03-27
WO1994005791A2 (en) 1994-03-17
AU4846593A (en) 1994-03-29
JPH08504086A (ja) 1996-05-07

Similar Documents

Publication Publication Date Title
US6500640B1 (en) Nucleic acid molecules encoding modified dorsal tissue affecting factor
US5843775A (en) Human dorsal tissue affecting factor (noggin) and nucleic acids encoding same
US5670481A (en) Dorsal tissue affecting factor (noggin) and compositions comprising same
CA2248549A1 (en) Extracellular matrix signalling molecules
US6566098B1 (en) DNA encoding truncated hepatocyte growth factor variants
EA001204B1 (ru) Усеченный нейротрофический фактор глиальной клеточной линии, днк, кодирующая указанный фактор, вектор, содержащий указанную днк, способ получения фактора, фармацевтическая композиция и способ лечения
US20110262432A1 (en) mutated netrin 4 proteins, fragments thereof and their uses as drugs
JPH06506470A (ja) TGF−β1/β2:新規なキメラトランスフォーミング増殖因子−β
US6008339A (en) Nucleic acids encoding a neural tissue affecting factor
CA2143442C (en) Dorsal tissue affecting factor and compositions
US6080845A (en) Monoclonal antibody against utricular epithelium
US20020128439A1 (en) Endoderm, cardiac and neural inducing factors - human frazzled (frzb-1) protein
WO1995015176A1 (en) Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
JPH05229957A (ja) Mkタンパク質
JPH05213771A (ja) ヘパリン結合性神経突起の成長プロモーター因子

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees